Kv3 Channel Modulator Compounds for Potency and Safety
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for alternative modulators of Kv3.1, Kv3.2, and/or Kv3.3 channels that demonstrate high in vivo potency, channel selectivity, improved safety profiles, and desirable pharmacokinetic parameters, such as high brain availability and low clearance rates, to effectively treat conditions like hearing disorders, schizophrenia, pain, and neurodegenerative disorders.
Innovation Solution
Development of compounds of formula (I), which can be in the form of salts, solvates, or derivatives, that act as modulators of Kv3.1, Kv3.2, and/or Kv3.3 channels, potentially offering balanced modulatory effects or specific selectivity for these channels, and are suitable for pharmaceutical compositions to treat conditions like hearing loss, tinnitus, schizophrenia, pain, and neurodegenerative disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing Kv3 channel modulators are used, then channel modulation effect is achieved, but in vivo potency and safety profiles are insufficient
Solution Approach 1:
The patent modifies chemical parameters of Kv3 channel modulators by introducing specific substituent groups (R1-R6) at defined positions on the core molecular structure. These parameter changes in molecular composition aim to achieve both high in vivo potency and improved safety profiles simultaneously, resolving the contradiction between effectiveness and safety.
Solution Approach 2:
The patent applies local quality by introducing specific functional groups at particular positions (R1 at position 2, R2-R3 at position 3, R4-R6 at position 4) of the molecular structure. Each position can be independently optimized to achieve desired pharmacological properties, allowing selective enhancement of potency while maintaining safety.
2Reliability
If channel selectivity is increased to treat specific disorders, then therapeutic efficacy is improved, but complexity of compound design increases
Solution Approach 1:
The patent segments the molecular design into distinct modular components: a core structure with independently variable substituent positions (R1-R6). Each substituent position can be optimized separately for channel selectivity, allowing systematic achievement of therapeutic efficacy without overwhelming design complexity.
Solution Approach 2:
The patent creates a universal molecular platform that can target multiple Kv3 channel subtypes (Kv3.1, Kv3.2, Kv3.3) through systematic substitution patterns. This multi-functional approach allows the same core structure to achieve selectivity across different channel types, simplifying the design process while maintaining therapeutic efficacy.
Data Source
AI summary
Disclosed is a compound of formula (I)Wherein R1 is H or methyl, R2 and R3 are both methyl, or R2 and R3, together with the carbon atom to which they are attached, are a spirocyclopropyl ring, R4 is methyl or ethyl, R5 is H or methyl, or R4 and R5, together with the carbon atom to which they are attached, form a C3-C4 spiro carbocyclyl. Also disclosed are methods for treating and/or preventing one or more diseases or disorders comprising administering to a subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, solvate and/or derivative thereof. Additionally, methods of using a compound of formula (I) to manufacture medicaments are provided.